Lusutrombopag

Lusutrombopag is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures. It is being manufactured and marketed in Japan by Shionogi under the trade name Mulpleta.[1][2][3] It was approved by the FDA in July 2018.[4]

Lusutrombopag
Clinical data
Trade namesMulpleta
Routes of
administration
Oral
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC29H32Cl2N2O5S
Molar mass591.54 g·mol−1
3D model (JSmol)
 NY (what is this?)

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.